Black Swan Biotech is a Perth-based biotechnology company established as a spin-out from the Perron Institute and Murdoch University.
Black Swan Biotech is developing next-generation PMO (phosphorodiamidate morpholino oligomer) therapies for CNS diseases, with a primary focus on Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Powered by NeuroPMO™ and a precision medicine approach, we are advancing targeted therapies designed to address the underlying biological drivers of neurodegenerative disease.
Whether you're interested in research collaboration, strategic partnerships, investment opportunities, or learning more about our technology, we'd love to hear from you.
